Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "inhibitor" wg kryterium: Temat

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-7 z 7
    Tytuł:
    The first line therapy for intermediate/ high risk patients with advanced renal cell carcinoma according to therapeutic program B.10
    Autorzy:
    Żołnierek, Jakub
    Powiązania:
    https://bibliotekanauki.pl/articles/22792533.pdf
    Data publikacji:
    2023-08-19
    Wydawca:
    Medical Education
    Tematy:
    renal cell carcinoma
    intermediate risk group
    unfavourable risk group
    tyrosine kinases inhibitor
    immune check-point inhibitor
    Opis:
    The purpose of this article is to discuss the use of therapeutic options for the first-line systemic treatment of patients with advanced renal cell carcinoma under the B.10 drug program effective in Poland as of May 2022 - with a focus on intermediate and high-risk patient populations according to the IMDC. The specific situation created by reimbursement conditions with the exclusion of regimens combined with a tyrosine kinase inhibitor and immune checkpoint inhibitors along with the marginalisation of the use of an mTOr inhibitor necessitates a choice between two-drug immunotherapy or an antian giogenic drug in monotherapy. In this context, choosing the right treatment in the context of specific clinical situations is a challenge.
    Źródło:
    OncoReview; 2023, 13, 2; 48-57
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Apalutamide in the treatment of a patient with non-metastatic castration-resistant prostate cancer
    Autorzy:
    Dziura, Robert
    Powiązania:
    https://bibliotekanauki.pl/articles/22676763.pdf
    Data publikacji:
    2023-03-31
    Wydawca:
    Medical Education
    Tematy:
    prostate cancer
    castration-resistant
    androgen receptor inhibitor
    Opis:
    The treatment of patients with prostate cancer, who do not qualify for the radical therapy is based on the use of surgical or pharmacological castration methods. The effectiveness of the so-called androgen deprivation tends to decrease over time. Even in the absence of distant metastases on imaging studies, the resistance for the hormonal castration may be developed. At this moment, the use of new generation androgen receptor inhibitors may reduce the risk of metastases or death. The paper presents a case report of a patient with prostate cancer without distant metastases who started therapy with apalutamide at the moment of developing re-sistance to the pharmacological castration.
    Źródło:
    OncoReview; 2023, 13, 1; 20-23
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Nowe możliwości leczenia uogólnionego raka piersi
    New possibilities of therapy for advanced, metastatic breast cancer
    Autorzy:
    Kuc-Rajca, Małgorzata
    Walaszkowska-Czyż, Anna
    Powiązania:
    https://bibliotekanauki.pl/articles/1066145.pdf
    Data publikacji:
    2013
    Wydawca:
    Medical Education
    Tematy:
    ewerolimus
    inhibitor mTOR
    pertuzumab
    rak piersi
    trastuzumab
    Opis:
    Despite improving screening methods, diagnosis of early breast cancers, new therapies the prognosis in breast cancer remains poor. Advanced, metastatic breast cancer is an incurable, persistent disease. Hormonotherapy is the main treatment of receptor positive breast cancer patients. Till now in case of hormone resistant disease chemotherapy was the only choice nowadays there is possibility to use combination of endocrine and targeted therapy, the mTOR inhibitor everolimus. In HER2 receptor positive breast cancer therapy with trasuzumab improved treatment results. Despite many new treatment methods there is still need for new therapies which could improve the patients outcome.
    Mimo udoskonalania metod badań przesiewowych, wczesnego wykrywania raka piersi i nowych terapii rokowanie w raku piersi pozostaje złe. Zaawansowany, uogólniony rak piersi jest chorobą przewlekłą, nieuleczalną. Podstawową metodą leczenia systemowego nowotworów dodatnich receptorowo jest hormonoterapia. Do niedawna w przypadku oporności metodą z wyboru pozostawała chemioterapia, obecnie możliwe jest zastosowanie skojarzenia leczenia hormonalnego z leczeniem celowanym ewerolimusem – inhibitorem mTOR. W rakach z nadekspresją receptora HER2 rokowanie pacjentek zmieniło wprowadzenie do leczenia trastuzumabu. Mimo dostępności wielu metod leczenia nadal poszukuje się nowych, które poprawią wyniki leczenia.
    Źródło:
    OncoReview; 2013, 3, 1; 59-62
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib-sorafenib sequence
    Autorzy:
    Kardas, Joanna
    Buraczewska, Agnieszka
    Powiązania:
    https://bibliotekanauki.pl/articles/1065215.pdf
    Data publikacji:
    2015
    Wydawca:
    Medical Education
    Tematy:
    clear cell carcinoma
    mTOR inhibitor (mTORi)
    metastatic renal cell cancer
    overall survival (OS)
    progression free survival (PFS)
    tyrosine kinase inhibitor (TKI)
    Opis:
    We presented a 39-year-old male who developed progressive cancer disease 4 years after nephrectomy due to clear cell carcinoma. He was diagnosed with locally reccurence and metastases to the liver, spleen and abdominal muscles. The patient was treated with sunitinib and then after disease progression – with sorafenib. We observed 18 months of cancer control (TKI-TKI). After second progression everolimus was administered. Third line everolimus therapy helped to achieve durable stable disease with PFS 46 months till now (May 2015). The patient remains in very good performance status with minimal toxicity from the regimen. This case illustrates a long term survival for patients with metastatic renal cell carcinoma, a malignancy with historically poor prognosis. The use of three sequential targeted therapies (TKI – TKI – mTORi) helped to achieve over 5 years or disease control, with rarely seen long-term response to third line treatment (mTORi) – where stabilization is good enough. We discussed therapeutic strategies in metastatic renal cell carcinoma according to the literature and therapeutic possibilities in Poland.
    Źródło:
    OncoReview; 2015, 5, 2; A71-75
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Prostate cancer in clinical practice. First experiences with apalutamide within the context of therapeutic program B.56
    Autorzy:
    Trzebiński, Krzysztof
    Powiązania:
    https://bibliotekanauki.pl/articles/22676841.pdf
    Data publikacji:
    2023-04-01
    Wydawca:
    Medical Education
    Tematy:
    non-metastatic castration-resistant prostate cancer
    apalutamide
    androgen receptor inhibitor
    Opis:
    The article contains a case report of patient diagnosed with castration-resistant non-metastatic prostate cancer, treated with a novel androgen receptor inhibitor – apalutamide.
    Źródło:
    OncoReview; 2023, 13, 1; 27-30
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    The evaluation of the efficacy and toxicity of targeted treatment in non-small cell lung cancer patients – single centre experience
    Autorzy:
    Kardas, Joanna
    Buraczewska, Agnieszka
    Chrom, Paweł
    Waśko-Grabowska, Anna
    Młot, Beata
    Szczylik, Cezary
    Powiązania:
    https://bibliotekanauki.pl/articles/773534.pdf
    Data publikacji:
    2017
    Wydawca:
    Medical Education
    Tematy:
    endothelial growth factor receptor
    non-small cell lung cancer
    tyrosine kinase inhibitor
    Opis:
    Introduction: Tyrosine kinase inhibitors (TKI) are the standard of treatment in patients with advanced non-small cell lung cancer (NSCLC) with EGFR (endothelial growth factor receptor) gene activating mutation. Objective: The evaluation of the efficacy and toxicity of TKI drugs in NSCLC patients treated in single centre. Material and methods: NSCLC patients treated with TKI (gefitinib, erlotynib, afatinib) between 2012– 2016 were retrospectively analysed. We evaluated: overall response rate (ORR) which is the sum of complete responses (CR) and partial remissions (PR), progression free survival (PFS), overall survival (OS) and adverse events (AE) according to CTCAE (Common Terminology Criteria for Adverse Events) scale. Results: The study group were 16 patients ORR was 50% (CR: 1, PR: 7). Median PFS and OS was 8,7 and 22,9 months respectively. Adverse events observed mainly in stage 1 and 2 were related to hyponatraemia, hyperbilirubinemia, skin toxicity and mucositis. There was one death reported due to infectious complications. Conclusion: The efficacy and toxicity of TKI in study group were found to be similar to those described in the literature.
    Źródło:
    OncoReview; 2017, 7, 2; 92-97
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Poly(adP-ribose) polymerase inhibitor olaparib in the treatment of ovarian cancer: a comprehensive review of current literature
    Autorzy:
    Poboży, Kamil
    Domańska, Julia
    Domański, Paweł
    Powiązania:
    https://bibliotekanauki.pl/articles/22792529.pdf
    Data publikacji:
    2023-07-02
    Wydawca:
    Medical Education
    Tematy:
    Olaparib
    PARP inhibitor
    ovarian cancer
    targeted therapy
    poly(ADP-ribose) polymerase
    cancer therapy
    Opis:
    Purpose of the review: This comprehensive review aims to provide a summary of current research on the utilization of olaparib, a poly(ADP-ribose) polymerase (PArP) inhibitor, in the treatment of ovarian cancer. The review aims to highlight the key findings from recent clinical trials and assess the potential of olaparib as a targeted therapy for improving the prognosis of ovarian cancer patients. recent findings: Ovarian cancer remains a significant global health concern with high mortality rates. While optimal debulking surgery and platinum-based chemotherapy are the standard treatments, the recurrence rates remain substantial. The emergence of PArP inhibitors, particularly olaparib, has intro duced a novel therapeutic approach that targets the genomic instability and DnA repair mechanisms in cancer cells. notable clinical trials, such as SOl O1, SOl O2, and PAOlA-1, have demonstrated the effectiveness of olaparib in significantly improving progression-free survival, particularly in patients with Br CA mutations or homologous recombination deficiency. Additionally, combination therapies involving olaparib, such as those with bevacizumab or entinostat, have shown promising results. Summary: The utilization of olaparib has brought about a paradigm shift in the treatment of ovarian cancer. notably, it has shown significant improvements in progression-free survival and overall survival, particularly in patients with Br CA mutations or homologous recombination deficiency. The exploration of olaparib through various clinical trials and combination therapies continues to provide valuable insights and offer new prospects for ovarian cancer patients. Moreover, the growing understanding of PArP inhibitors holds the potential for further advancements in the prognosis of patients with this formidable condition.
    Źródło:
    OncoReview; 2023, 13, 2; 39-47
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-7 z 7

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies